IgA Vasculitis Nephritis (Henoch-Schönlein Purpura)

1. Executive Overview: Understanding IgA Vasculitis Nephritis

IgA Vasculitis (IgAV), formerly known as Henoch-Schönlein Purpura (HSP), is a systemic small-vessel vasculitis characterized by the deposition of immunoglobulin A (IgA1)-dominant immune complexes. While the condition is often self-limiting in its cutaneous and gastrointestinal manifestations, the involvement of the renal parenchyma—termed IgA Vasculitis Nephritis (IgAVN)—represents the most significant long-term clinical concern.

In clinical nephrology, IgAVN is recognized as a form of immune-complex-mediated glomerulonephritis. It is distinct from primary IgA Nephropathy (Berger’s Disease) in its systemic presentation, yet they share overlapping histological features. The renal involvement can range from asymptomatic microscopic hematuria to rapidly progressive glomerulonephritis (RPGN) and end-stage kidney disease (ESKD). This guide provides a clinical framework for understanding the pathophysiology, diagnostic pathways, and therapeutic management of IgAVN.

2. Pathophysiology, Etiology, and Risk Factors

The pathogenesis of IgAVN is rooted in the "multi-hit" hypothesis, similar to primary IgA nephropathy.

The Pathophysiological Cascade

1. Production of Galactose-Deficient IgA1 (Gd-IgA1): The process begins with the systemic production of aberrantly glycosylated IgA1 molecules.
2. Autoantibody Formation: The body produces IgG or IgA autoantibodies directed against the exposed hinge-region glycans of Gd-IgA1.
3. Immune Complex Formation: These form circulating immune complexes that deposit in the glomerular mesangium.
4. Complement Activation: The deposition triggers the alternative and lectin complement pathways, leading to the recruitment of inflammatory cells, cytokine release (IL-6, TNF-α), and subsequent glomerular injury.

Histopathological Impact

The injury pattern is primarily glomerular. The mesangial proliferation is the hallmark, but severe cases progress to crescentic glomerulonephritis, where fibrin and inflammatory cells fill Bowman’s space, leading to rapid loss of renal function. Tubular pathology is often secondary, resulting from ischemia or protein-rich tubule-interstitial inflammation.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of IgAVN is highly variable, ranging from incidental findings to acute renal failure.

• Nephritic Presentation: Characterized by hematuria, hypertension, and reduced GFR. It often presents with "cola-colored" urine.
• Nephrotic Presentation: Characterized by heavy proteinuria (>3.5g/day), hypoalbuminemia, and peripheral edema. This indicates significant podocyte injury.
• Systemic Symptoms: The "classic tetrad" includes palpable purpura (lower extremities), arthralgia, abdominal pain (intussusception risk), and renal involvement.

Clinical Red Flags:
* Rapid rise in serum creatinine (sCr) over days/weeks.
* Development of sustained hypertension.
* Proteinuria exceeding 1g/24h.

4. Diagnostic Evaluation and Workup

A systematic approach is required to differentiate IgAVN from other glomerulonephritides.

Laboratory Assays

• Urinalysis: Microscopic hematuria (dysmorphic RBCs) and proteinuria are early markers.
• Serum Chemistry: Monitoring eGFR (using CKD-EPI equation) and baseline creatinine.
• Immunological Panel: C3 and C4 levels (usually normal), ANA, ANCA, and ASO titers to rule out Lupus Nephritis or Post-Streptococcal Glomerulonephritis.

Renal Biopsy: The Gold Standard

A biopsy is indicated if there is significant proteinuria (>0.5-1g/day), persistent hematuria, or declining eGFR.
* Immunofluorescence (IF): Confirms dominant IgA deposits in the mesangium.
* Light Microscopy: Used for the ISKDC (International Study of Kidney Disease in Children) or Oxford MEST-C scoring to predict progression.

Imaging

• Renal Ultrasound: Essential to assess kidney size (chronicity marker) and rule out urinary tract obstruction.

5. Therapeutic Interventions

Management is dictated by the severity of the renal lesion.

Pharmacotherapy

1. Supportive Care: RAAS inhibition (ACE inhibitors or ARBs) is the first-line therapy for patients with proteinuria to reduce intraglomerular pressure and provide renoprotection.
2. Immunosuppression: Reserved for patients with severe histological findings (crescents) or nephrotic-range proteinuria.
   • Corticosteroids: Oral prednisone or pulse IV methylprednisolone for rapid control of inflammation.
   • Cyclophosphamide: Often used in cases of RPGN (Rapidly Progressive Glomerulonephritis).
   • Mycophenolate Mofetil (MMF): An alternative steroid-sparing agent for maintenance.
3. Blood Pressure Control: Strict targets (typically <130/80 mmHg) are essential to prevent CKD-MBD (Mineral and Bone Disorder).

Lifestyle and Monitoring

• Sodium Restriction: <2g/day to manage hypertension and edema.
• Serial Monitoring: Quarterly evaluation of UPCR (Urine Protein-to-Creatinine Ratio) and eGFR.

6. Frequently Asked Questions (FAQ)

1. Is IgA Vasculitis Nephritis the same as Berger’s Disease?

While both involve IgA deposits, IgAVN is a systemic vasculitis with extra-renal symptoms (rash, joint pain), whereas Berger’s disease is typically limited to the kidneys.

2. Can IgAVN be cured?

In many cases, the renal involvement resolves with treatment. However, some patients may progress to chronic kidney disease (CKD) and require long-term management.

3. What is the role of the renal biopsy?

Biopsy is crucial to determine the severity of histological damage (crescents, scarring), which dictates the intensity of immunosuppressive treatment.

4. What does "nephrotic syndrome" mean in this context?

It means the kidneys are leaking large amounts of protein into the urine, leading to low blood protein levels and significant swelling (edema).

5. How does IgAVN affect long-term kidney function?

Untreated or severe cases can lead to scarring (fibrosis), resulting in decreased eGFR and potential progression to End-Stage Kidney Disease (ESKD).

6. Are there specific dietary restrictions?

Patients should follow a low-sodium, heart-healthy diet. If renal function is significantly impaired, protein intake may need to be adjusted under clinical supervision.

7. Does the rash indicate kidney damage?

The rash is a sign of systemic vasculitis. While not all patients with the rash develop kidney issues, it is a clinical indicator that requires thorough renal monitoring.

8. What is the significance of the MEST-C score?

The MEST-C score is a standardized histological grading system used by pathologists to predict how likely the disease is to progress based on specific findings in the biopsy tissue.

9. Why are ACE inhibitors or ARBs prescribed?

These medications are not just for blood pressure; they directly reduce protein leakage and provide renoprotection by dilating the efferent arteriole in the glomerulus.

10. How often do I need to see a nephrologist?

Follow-up frequency is determined by the severity of your disease. Patients with active proteinuria or declining eGFR are usually seen every 1–3 months.

Disclaimer: This guide is for educational purposes only and does not replace professional medical advice. If you suspect kidney involvement, please consult a board-certified nephrologist immediately. Diagnosis and treatment must be personalized based on clinical history and biopsy results.